Imipenem/cilastatin in the treatment of obstetric and gynecologic infections: a review of worldwide experience.

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Worldwide experience with imipenem/cilastatin in the treatment of 72 patients with a variety of obstetric and gynecologic infections is reviewed. Clinical cure or improvement occurred in 97% of 72 assessable patients. The most common etiologic pathogens were Escherichia coli, group B streptococci, Neisseria gonorrhoeae, Staphylococcus epidermidis, enterococci, Bacteroides bivius, Bacteroides species, Bacteroides fragilis, and Peptostreptococcus. Of the recovered pathogens, 99.5% were susceptible to imipenem/cilastatin. Bacteriologic response was also excellent and none of the pathogens acquired resistance to imipenem. Most patients tolerated intravenous administration of imipenem/cilastatin well to moderately well.

Original languageEnglish (US)
JournalReviews of Infectious Diseases
Volume7 Suppl 3
StatePublished - Jul 1985
Externally publishedYes

ASJC Scopus subject areas

  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Imipenem/cilastatin in the treatment of obstetric and gynecologic infections: a review of worldwide experience.'. Together they form a unique fingerprint.

Cite this